The US Food and Drug Administration has approved a second indication for the Novartis immunosuppressant everolimus: to prevent organ rejection in adult liver transplant patients. The same indication was approved in Europe in late 2012. ---Subscribe to MedNous to access this article--- Company News Regulation & Policy
